PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric Adenocarcinoma
Status:
Recruiting
Trial end date:
2022-07-30
Target enrollment:
Participant gender:
Summary
This is a prospective single arm phase II clinical study to compare the safety and efficacy
of PD-1monoclonal antibody +FLOT in patients with gastric adenocarcinoma/esophagus-gastric
junction adenocarcinoma.